B+
Bull case
25%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
OABI
OmniAbFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is that OmniAb’s 107 active partners, 407 active programs and growing set of later-stage partnered assets can gradually convert a low-revenue platform story into a milestone-and-royalty story, while OmniUltra and xPloration widen platform relevance and help sustain partner additions [#8-K-2026-03-04].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
Momentum
100
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.40 · Bear $0.70Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.64
Why
Momentum100 · Δ7d -0.1
Value41 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • 2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
- • Competition in antibody discovery and screening remains intense across transgenic platforms and related discovery technologies [#10-K-2026-03-04].
- • The bear case is that OmniAb remains dependent on partner-controlled development events, posted lower 2025 revenue, and guided to another year of material cash burn; if partner timelines slip or monetization from newer offerings stays modest, the stock can remain trapped in a low-conviction monitoring range with financing risk creeping higher [#8-K-2026-03-04].
Catalyst clock
2026-06-30
H1 2026 partner readouts are the nearest sentiment test
Lead driver: Value · See fundamentals
Momentum
100
9% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-
Why this grade
Composite grade F. Momentum 99.6 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$555.39M
Beta
0.15
Shares Out
145.39M
P/E (TTM) · Derived
-6.7
P/S (TTM)
12.63
P/FCF (TTM) · Derived
-25.33
Rev YoY
+244.2%
EPS YoY
-69.6%
Gross Margin
+36.4%
Op Margin
-126.0%
Net Debt
-$33.69M
Current Ratio
4.80
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data